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Abstract
Genetic alterations conferring resistance to the effects of chemical inhibitors are valuable
tools for validating on-target effects in cells. Unfortunately, for many therapeutic targets
such alleles are not available. To address this issue, we evaluated whether CRISPR-Cas9-
mediated insertion/deletion (indel) mutagenesis can produce drug-resistance alleles at
endogenous loci. This method takes advantage of the heterogeneous in-frame alleles pro-
duced following Cas9-mediated DNA cleavage, which we show can generate rare alleles
that confer resistance to the growth-arrest caused by chemical inhibitors. We used this
approach to identify novel resistance alleles of two lysine methyltransferases, DOT1L and
EZH2, which are each essential for the growth of MLL-fusion leukemia cells. We biochemi-
cally characterized the DOT1L mutation, showing that it is significantly more active than the
wild-type enzyme. These findings validate the on-target anti-leukemia activities of existing
DOT1L and EZH2 inhibitors and reveal a simple method for deriving drug-resistance alleles
for novel targets, which may have utility during early stages of drug development.
Introduction
One key aspect of evaluating small molecule inhibitors is the verification of on-target effects in
cells. This can be addressed by generating genetic alterations conferring resistance to the
inhibitors, and testing whether expression of such alleles can rescue the cellular effects of the
inhibitor. Currently, there are two conventional strategies for generating such chemical inhibi-
tor resistant mutations: (i) Expressing a randomly mutagenized cDNA library of the suspected
drug target in cells, followed by selection for resistance phenotypes [1,2], or (ii) Identifying
genetic mutation(s) from spontaneously emerging resistant cell populations produced under
continuous exposure to the chemical inhibitor [3]. While both methods have been successfully
employed in identifying chemical inhibitor resistant mutations, such as identifying the imati-
nib-resistant BCR-ABL in chronic myeloid leukemia [1] or the vemurafenib-resistant BRAF
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mutants in melanoma [4], some limitations still persist. For example, achieving the proper
expression level of the ectopically expressed cDNA is critical to confer resistance. Moreover,
spontaneous mutations that confer resistance may occur in genes unrelated to the drug’s direct
target, as is the case in mutations that induce an up-regulation in transporter proteins that can
pump the inhibitor out of the cell.
Here, we present a simple method that employs CRISPR-Cas9 (clustered regularly inter-
spaced short palindromic repeats) mutagenesis to derive resistance-conferring alleles of en-
dogenous genes for demonstrating the on-target effects of compounds in cells. CRISPR-Cas9
is an RNA-guided endonuclease system that is widely used for genome editing [5,6]. In this
system, a programmable single guide RNA (sgRNA) directs a Cas9 protein to desired genomic
regions and produces a double-strand DNA break (DSB). Through the error-prone non-
homologous end joining repair pathway, a collection of indel mutations are introduced to
regions flanking the Cas9-mediated DSB site [7–9]. Directing these CRISPR-induced indel
mutations to protein-coding regions generates both in-frame and frame-shift mutations of
the gene being targeted [10–12]. By taking advantage of functionally intact in-frame indels
[11,13], we hypothesized that the diversity of indels induced by CRISPR mutagenesis could be
used to select for chemical inhibitor-resistant allele(s), and subsequently, could be used for
evaluating the on-target effects of corresponding chemical inhibitors. In this work, we derived
reproducible inhibitor-resistant alleles of two lysine methyltransferases (KMT), DOT1L and
EZH2, through domain-focused CRISPR indel mutagenesis. Through CRISPR-based positive
selection screens, we found a recurring DOT1L mutation, VVEL293MM, which conferred
resistance to a DOT1L inhibitor, EPZ-5676 [14]. Biochemical experiments suggested that the
DOT1L VVEL293MM mutant was a hypermorphic mutant, as it alleviated the growth arrest
effect of EPZ-5676 mainly by increasing the basal level of key methylated DOT1L substrate.
Furthermore, we extended our method to identify an EZH2 mutant that rendered leukemia
cells resistant to an EZH2 inhibitor, EPZ-6438 [15]. Taken together, we show that domain-
focused CRISPR-Cas9 indel mutagenesis allows for a straightforward and rapid identification
of drug-resistant alleles, making it a useful tool for the evaluation of on-target drug activity.
Materials and methods
Plasmids
The constitutive, human codon-optimized, Streptococcus pyogenes Cas9 retroviral expression
construct (MSCV-hCas9-PGK-Puro, Addgene: #65655) and lentiviral sgRNA expression vec-
tor (LRG, Addgene: #65656) were adapted from previous work [11]. The wild-type human
DOT1L cDNA was cloned into a lentiviral expression vector with EFS prompter and P2A-
linked Puromycin resistance gene. P2A, porcine teschovirus-1 2A. The wild-type EHZ2 cDNA
was cloned into an MSCV-based vector containing a puromycin-resistance gene and a GFP
reporter as previously reported [16]. Both the DOT1L VVEL293MM DOT1L and EZH2
TR683KK mutations were introduced by standard PCR mutagenesis. The PCR cloning proce-
dures were performed using the In-Fusion1 HD Cloning Kit (Clontech: #638909). For the
recombinant DOT1L KMT domain, wild-type and VVEL293MM mutant cDNA were cloned
into the bacterial expression vector pET-22b (Novagen) via sequence- and ligation-Indepen-
dent cloning, which contained an N-terminal His6-tag and TEV protease site that allowed for
affinity purification and subsequent cleavage of the affinity tag.
Single and pooled CRISPR sgRNA cloning
Plasmids expressing a single sgRNA were cloned by annealing two DNA oligos and ligating
into a BsmB1-digested LRG vector. To improve U6 promoter transcription efficiency, an extra
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5’ G nucleotide was added to all sgRNAs that did not start with a 5’ G. For the pooled sgRNAs
targeting the KMT domain of either DOT1L or EHZ2, all possible sgRNAs were designed
based on a PAM sequence of NGG that is recognized by the S. pyogenes Cas9 protein. The
sgRNAs were synthesized individually, annealed to complementary sgRNAs, pooled in equal
molar ratios, and ligated into BsmB1-digested LRG vectors. All sgRNA sequences used in this
study are provided in S1 Table.
Cell culture and virus production
All cell lines used in this study were tested as mycoplasma negative. The RN2c cell line was
adapted from previous study [11]. Briefly, murine MLL-AF9/NrasG12D acute myeloid leukemia
cells (RN2) [17] were transduced with MSCV-hCas9-PGK-Puro, followed by puromycin
selection. A single cell-derived clone was derived by serial dilution. RN2 and RN2c cells were
cultured in RPMI1640 supplemented with 10% fetal bovine serum (FBS) and penicillin/
streptomycin.
Plat-E cells were used for retroviral delivery of hCas9 or EZH2 cDNA expression vectors,
following standard procedures [18]. HEK293T cells were used for lentiviral production of
sgRNA or DOT1L expression vectors. Ecotropic Plat-E cells and HEK293T cells were cultured
in DMEM supplemented with 10% FBS and penicillin/streptomycin. Lentivirval vectors were
mixed with pVSV-G and psPAX2 in a 4:2:3 ratio using PEI reagent (Polysciences, #23966).
Viral supernatants were collected at 36, 48, 60, and 72 hours post-transfection. RN2 cells were
transduced with empty or indicated cDNA overexpression vectors, followed by puromycin
selection for ectopic cDNA overexpression. To measure the relative cell accumulation, cDNA-
transduced RN2 cells were counted at the initial and end experimental time points using a
Guava Easycyte HT instrument (Millipore). Gating was performed on live cells using forward
and side scatter together with propidium iodide to exclude dead cells. The relative cell ac-
cumulation of each experimental condition was calculated by normalizing to the untreated
condition.
Pooled sgRNA screening, Miseq library construction, and data analysis
Virus containing the pooled sgRNA library was generated as described above. Serial dilution
of this virus in correlation with the GFP+ cell population was used to estimate the viral titer
multiplicity of infection (MOI). In the initial infected cell population, the total number of
RN2c cells corresponded to an approximately 1 million-fold representation of each sgRNA. To
ensure that a single sgRNA was transduced per cell, the viral volume for infection corre-
sponded to an MOI of 0.5. At 3 days post-infection, RN2c cells were treated with chemical
inhibitors, while a small portion of the RN2c cells was harvested and used as a reference time
point (day 0). Likewise, at later time points, when the sgRNA+/GFP+ and inhibitor-resistant
cell population emerged, a small portion of the cells was harvested again and saved for subse-
quent deep sequencing experiments. The sgRNA+/GFP+ cell population was monitored over
the experimental time course using a Guava Easycyte HT instrument (Millipore). Gating was
performed on live cells using forward and side scatter together with propidium iodide to
exclude dead cells, prior to measurement.
The sgRNA cassette MiSeq deep sequencing library was constructed using a similar method
as previously described [11]. Genomic DNA was extracted using QiAamp DNA mini kit (Qia-
gen #51304), following the manufacturer’s protocol. In order to maintain >1000-fold sgRNA
library representation, 20 parallel PCR reactions were performed to amplify the sgRNA cas-
sette using the 2X High Fidelity Phusion Master Mix (Thermo Scientific #F-548). PCR prod-
ucts were subjected to Illumina MiSeq library construction and sequencing. First, the PCR
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product was end repaired with T4 DNA polymerase (New England BioLabs, NEB), DNA poly-
merase I (NEB), and T4 polynucleotide kinase (NEB). Then, an adenosine overhang was
added to the end-repaired DNA using Klenow DNA Pol Exo- (NEB). The overhanging DNA
fragment was ligated with diversity-increased barcoded Illumina adaptors followed by seven
pre-capture PCR cycles. The barcoded libraries were pooled at an equal molar ratio and sub-
jected to massively parallel sequencing through a MiSeq instrument (Illumina) using paired-
end 75-bp sequencing (MiSeq Reagent Kit v3; Illumina MS-102-3001).
The sequence data were de-barcoded and trimmed to contain only the sgRNA sequence,
and subsequently mapped to the reference sgRNA library without allowing any mismatches.
The read counts were calculated for each individual sgRNA. To calculate the relative abun-
dance of each sgRNA, the read counts of each sgRNA were divided by the total read counts of
the pooled sgRNA library. The primer and diversity-increased barcode information are listed
in S1 Table.
MiSeq analysis of CRISPR-induced mutations
A deep sequencing method was used to identify the DOT1L mutants associated with EPZ-
5676 resistance, as described previously [11]. The genomic region of DOT1L exon 8 was PCR
amplified with High Fidelity 2X Phusion Master Mix (Thermo Scientific #F-548) and sub-
jected to MiSeq library construction as described above. Barcoded libraries were pooled at an
equimolar ratio and subjected to massively parallel sequencing by MiSeq (Illumina) using
paired-end 150-bp sequencing (MiSeq Reagent Kit v2; Illumina MS-102-2002).
Data analysis was performed as described previously [11]. Paired-end Illumina reads were
aligned to the DOT1L genomic locus and variant sequences were called. Variant sequences
were recorded in the tab “DOT1L mutations pooled screen” of (for the pooled sgRNA experi-
ment) or in tab “DOT1L mutations sgRNA#47” of (for the single sgRNA experiment) S1
Table,), if they were present in at least a total of 10 reads across the two time points and were
not present in the control sample.
Real-time PCR
RNA was prepared using Trizol reagent (Invitrogen). cDNA synthesis was performed using
qScript cDNA SuperMix (Quanta Biosciences, #101414–106). Quantitative PCR (qPCR) analy-
sis was performed on an ABI 7900HT with SYBE green (ThermoFisher, #4309155). All signals
were quantified using the delta-Ct method and normalized to the levels of Gapdh.
Expression and purification of recombinant DOT1L KMT domain
The DOT1L KMT domain constructs were transformed into E. coli BL21 (DE3)-RIPL cells for
protein expression. Cultures were grown in TB media with antibiotic at 37˚C until the OD600
was approximately 1.5. The cultures were then briefly cooled on ice and treated with 0.5 mM
isopropyl-β-d-1-thiogalactopyranoside (IPTG) to induce protein expression. Cultures were
then incubated overnight at 16˚C with shaking. After expression, the cell pellets were thawed,
resuspended in 20 mM Tris, pH 8.0, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 5 mM
βME (~20 mL per liter culture), and lysed by sonication. The cell lysate was clarified by ultra-
centrifugation at 140,000 g for 30 min and the supernatant was applied to a Ni-NTA (Qiagen)
column equilibrated with lysis buffer. The bound proteins were washed with lysis buffer, fur-
ther washed with lysis buffer containing 30 mM imidazole, and finally eluted in lysis buffer
containing 200 mM imidazole. The His6 tag was then removed by the addition of TEV prote-
ase (1:20 m/m ratio protease:DOT1L KMT) and overnight incubation at 4˚C.
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The proteins were further purified by ion exchange chromatography using a MonoS 5/50
GL column (GE Healthcare) equilibrated with 20 mM HEPES, pH 7.5, 1 mM EDTA, 1 mM
DTT. Bound proteins were fractionated by elution using a gradient of NaCl from 0 to 1 M.
Fractions corresponding to the target protein (around 45 mS) were pooled, concentrated, and
further purified by gel filtration using a Superdex200 increase column (GE Healthcare) equili-
brated with 20 mM HEPES, pH 7.5, 200 mM NaCl, 1 mM EDTA, 1 mM DTT.
The purified protein concentrations were determined by Aλ = 280 measurement and cor-
rected for the calculated molecular extinction coefficient. The proteins were then concentrated
to 10–20 mg/mL and stored at 4˚C until needed. Typical yields (with >98% purity as assessed
by SDS–PAGE) were 4 mg of the wild-type protein and 0.5 mg of the VVEL293MM mutant
protein per liter culture.
Methyltransferase activity assay
Methyltransferase activity assays with the purified DOT1L KMT domains were performed on
native nucleosome substrates purified from human HeLa cells (BPS Bioscience) using tritiated
S-adenosyl methionine (3H-SAM) (Perkin Elmer). To accurately determine the relative methy-
ltransferase activities of the wild-type and VVEL293MM mutant proteins, serial dilutions of
the enzymes were made under the same conditions. Each 10 μL reaction included 2 μL of
3H-SAM (1 μCi, ~1.3 mM final concentration) and 1 μg of the nucleosome substrate in a buffer
of 20 mM Tris, pH 8.0, 4 mM EDTA, 1 mM DTT, 0.01% Triton X-100. The enzyme concentra-
tion varied as a two-fold dilution series from 100 nM to 6.25 nM. After mixing all components,
the reactions were incubated at room temperature for 2 hours. Each reaction was then dena-
tured and subjected to SDS-PAGE followed by gel fixation, treatment with ENLIGHTNING
autoradiography enhancer (Perkin Elmer), drying, and autoradiography. The dried gels were
then exposed to BioMax XAR Film (Kodak, Carestream) for approximately 60 hours. After
developing, the films were scanned and band intensities were quantified using the ImageQuant
TL 8.1 analysis software package (GE Healthcare). The presented data reflect the average of
two replicates, error bars indicate the standard error of the mean, and the linear fit of the data
was constrained to pass through the origin.
Subsequently, to establish if the wild-type and mutant proteins exhibited differential sensi-
tivity to inhibitors, similar reactions were carried out in the presence of inhibitors at a fixed
protein concentration of 50 nM. As the relative activity of the VVEL293MM enzyme was
found to be roughly 3-fold higher than that of the wild-type protein, we sought to normalize
the total activity observed on our autoradiographs to better discern slight differences in the
proteins’ sensitivity to inhibitors. To accomplish this, reactions volumes were scaled such that
three-fold more material was loaded per gel lane for the wild-type samples. Inhibitor concen-
trations ranged from 400 nM to 50 nM as a two-fold dilution series. Sample processing was
performed as described above. The integrated band intensity for the uninhibited reactions was
then used to normalize the intensities of the inhibitor concentration series.
Probing neomorphic methyltransferase activity with mass spectrometry
Reaction preparation. To determine if the mutant enzyme exhibits a neomorphic activity
compared to the wild-type enzyme, a proteomic analysis of the methylation reactions was per-
formed. The nucleosome substrate (10 μg) in a buffer of 20 mM Tris, pH 8.0, 4 mM EDTA, 1
mM DTT, 0.01% Triton X-100 was reacted with the DOT1L wild-type enzyme (10 μM final
concentration) in the presence of (non-radiolabeled) S-adenosyl methionine at a concentra-
tion of 1 mM for two hours at room temperature in a reaction volume of 20 μL.
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Precipitation, digestion and iTRAQ labeling. Tris(2-carboxyethyl)phosphine (TCEP)
was added to each reaction at a final concentration of 5 mM. The samples were heated at 55˚C
for 20 min then allowed to cool to room temperature. Methyl methanethiosulfonate (MMTS)
was next added to a final concentration of 10 mM and the samples were incubated at room
temperature for 20 min to block free sulfhydryl groups. Proteins were then precipitated by the
addition of 10 volumes of 10% trichloroacetic acid (TCA) in acetone followed by incubation at
-20˚C for overnight. The samples were then centrifuged at 14,000 for 10 min at 4˚C and the
supernatant were removed. Ten volumes of ice cold acetone were added to the pellet which
was then vortexed. The precipitate was incubated at -20˚C for 10 minutes before centrifuging
at 4˚C and 14,000g for 5 minutes. The supernatant was removed and discarded without dis-
turbing the pellet, and the pellet was allowed to dry. The precipitated proteins were resus-
pended with 50 μL of 100 mM TEAB. The pellet was then sonicated until completely dissolved.
2 μg of sequencing grade trypsin (Promega) was then added to the samples. Digestion contin-
ued at 37˚C overnight after which the samples were and dried in vacuo. Peptides were resus-
pended in 50 μL of 0.5M TEAB/70% ethanol and labeled with 8-plex iTRAQ reagents for 2
hours at room temperature essentially according to Ross et al (2004). Labeled samples were
then acidified to pH 4 using formic acid, combined, and concentrated in vacuo until ~10 μL
remained.
Mass spectrometry. A Q-Exactive High Field mass spectrometer (Thermo Scientific)
equipped with a nano-ion spray source was coupled to an EASY-nLC 1200 system (Thermo
Scientific). The nano-flow LC system was configured with a self-pack PicoFrit™ 75 μm ana-
lytical column with an 8 μm emitter (New Objective, Woburn, MA) packed to 25 cm with
ReproSil-Pur C18-AQ, 1.9 μM material (Dr. Maish GmbH). Mobile phase A consisted of 2%
acetonitrile; 0.1% formic acid and mobile phase B consisted of 90% acetonitrile; 0.1% formic
acid. Peptides were then separated using the following linear gradient steps at a flow rate of
200 nL/min: 2% B to 6% B over 1 min, 6% B to 30% B over 84 min, 30% B to 60% B over 9
min, 60% B to 90% B over 1 min, held at 90% B for 5 min, 90% B to 50% B over 1 min and
then held at 50% B for 9 min.
Eluted peptides were directly electrosprayed into the Q-Exactive High Field mass spec-
trometer with the application of a distal 2.3 kV spray voltage and a capillary temperature of
300˚C. Each full-scan mass spectrum (Res = 60,000; 380–1700 m/z) was followed by MS/MS
spectra for the top 20 masses. High-energy collisional dissociation (HCD) was used with the
normalized collision energy set to 27 for fragmentation, the isolation width set to 1.2 and
activation time of 0.1. A duration of 15 seconds was set for the dynamic exclusion with an
exclusion list size of 500, repeat count of 1, and exclusion mass width of 10 ppm. We used
monoisotopic precursor selection for charge states 2+ and greater, and all data were acquired
in profile mode.
Probing neomorphic methyltransferase activity with autoradiography. As an alterna-
tive means to determine if the mutant possessed a new activity compared to the wild-type
enzyme, nucleosome substrates were first pre-reacted with the wild-type protein. The nucleo-
some substrate (50 μg) in a buffer of 20 mM Tris, pH 8.0, 4 mM EDTA, 1 mM DTT, 0.01% Tri-
ton X-100 was reacted with the DOT1L wild-type enzyme (10 μL final concentration) in the
presence of (non-radiolabeled) S-adenosyl methionine at a concentration of 1 mM overnight
at room temperature in a reaction volume of 100 μL.
After the overnight pre-reaction, the protein components of the reaction were isolated
using 7 kDa molecular weight cutoff Zeba spin desalting columns (ThermoFisher Scientific).
The pre-reacted nucleosomes were then used as the substrate for autoradiography assays as
described above.
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Results
KMT domain-focused CRISPR indel mutagenesis reveals a DOT1L
allele that confers resistance to EPZ-5676-mediated growth arrest
To test our strategy for identifying inhibitor-resistant alleles and dissecting the on-target effects
of a given chemical inhibitor, we selected the gene encoding DOT1L, a histone H3K79 methyl-
transferase [19], as our mutagenesis target. The DOT1L protein is essential for the growth of
MLL-rearranged leukemia cells and exerts its effect by maintaining active transcription of Hoxa9
and Meis1 [20,21]. There are several selective small molecule inhibitors of DOT1L, including
EPZ-5676, which is currently under clinical evaluation for treating MLL- rearranged leukemia
(ClinicalTrials.gov identifier NCT02141828). Recent studies have suggested that EPZ-5676
exhibits therapeutic effects in leukemia by inhibiting the methyltransferase activity of DOT1L
[14], however this has never formally been proven to be an on-target effect using a resistance-
conferring allele of DOT1L. Therefore, we evaluated the CRISPR indel mutagenesis method
by targeting DOT1L to generate mutant(s) that confer resistance to EPZ-5676. To begin, we
employed a codon optimized S. pyogenes Cas9-expressing murine MLL-AF9/NrasG12D acute
myeloid leukemia cell line (RN2c) [11] (Fig 1A). We designed all possible sgRNAs targeting the
methyltransferase domain of DOT1L (73 in total) based on a protospacer adjacent motif (PAM)
of NGG that is recognized by the S. pyogenes Cas9 protein. We cloned these sgRNAs as a pool
into a bicistronic lentiviral vector that links each sgRNA to a GFP reporter (Fig 1B). By measur-
ing the GFP-positive cell population, we were able to monitor the abundance of sgRNA positive
cells over time in culture. In order to assess a broad spectrum of mutations and potential rare,
Cas9-induced, in-frame mutations, we transduced the RN2c cells with the pooled CRISPR lenti-
virus using approximately 1 million cells per sgRNA. By monitoring the GFP-positive fraction of
the cell population, we profiled the abundance of sgRNA positive cells over time (Fig 1C).
We exposed the library-transduced cells to a low concentration of EPZ-5676 (100 nM),
which was then stepped-up to a higher concentration of 500 nM at day 20 (Fig 1C and 1D). As
expected, we observed that the sgRNA+/GFP+ cells became depleted during initial time points
of culturing, consistent with the majority of CRISPR-induced indels within the DOT1L KMT
domain resulting in loss-of-function, thereby causing an arrest of growth [11]. After this initial
crash of sgRNA+/GFP+ cells, we observed an eventual, progressive, return of sgRNA+/GFP
+ cell population at later time points. By day 60 post-transduction, the sgRNA+/GFP+ popula-
tion had reached>95% (Fig 1D). This pattern of decline and rebound of sgRNA+/GFP+ popu-
lation was suggestive that rare indel allele(s) of DOT1L produced by Cas9 mutagenesis had
conferred resistance to the growth arrest caused by EPZ-5676. Consistent with this possibility,
we observed that DOT1L-dependent genes Hoxa9, Meis1, and Mef2c were no longer sup-
pressed by EPZ-5676 in the cells recovered at day 60 of the experiment (Fig 1E).
To gain initial insight into the potential mechanism of CRISPR-Cas9-induced resistance to
EPZ-5676, we profiled the representation of the individual sgRNAs over the course of the
experiment. To this end, we PCR amplified the sgRNA cassette from genomic DNA that was
collected at day 0 and day 41 of the time-course then performed deep sequencing (Fig 1D).
While all 73 sgRNAs targeting the DOT1L KMT domain were detected at roughly equal abun-
dance at day 0, we found that a single sgRNA #47 was over-represented in the cell population
at day 41 of EPZ-5676 exposure. This suggested the possibility that sgRNA #47 had produced
an in-frame indel mutation of DOT1L that conferred resistance to EPZ-5676 (Fig 1F). Since
individual sgRNAs tend to produce a reproducible pattern of heterogeneous indel mutations
[22], we evaluated whether sgRNA #47 would confer resistance to EPZ-5676 when evaluated
individually in an independent experiment compared to control sgRNAs. Indeed, we found
that under continuous exposure to EPZ-5676, the leukemia cells transduced with DOT1L
Generation of rare drug-resistance alleles using CRISPR-Cas9 indel mutagenesis
PLOS ONE | DOI:10.1371/journal.pone.0172177 February 23, 2017 7 / 16
initial harvest
day 0
resistance harvest
day 41
DOT1L
#47
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
PAM
VVEL293MM
wild-type
DOT1L #47
A T T G G C A C C CA T A T G C G T G T G TG G G GA C T TG C G
I G T I M R V EV L S
– – – – – –C A AA T T G G C A C C CA T A T G C G T TG G T C G
I G T I M R M –M – S
cut site
Parental EPZ-5676 resistant
Hoxa9 Mef2c Meis1 Hoxa9 Mef2c Meis1
0
1
2
DMSO
1 µM EPZ-5676
500 nM EPZ-5676
5 µM EPZ-5676
3
)
%( noit al upop +
PF
G/ +
A
N
Rgs
Days
10
0
20
30
40
50
020 0301
Rosa26
DOT1L #47
DOT1L #64
Rosa26
DOT1L #47
DOT1L #64
DMSO EPZ-5676
EPZ-5676 (µM)
100
50
0
0 1 2 3 4 5
wild-type
VVEL293MM
R
el
at
iv
e 
ce
ll 
ac
cu
m
ul
at
io
n 
(%
)
Days
)
%( noit al upop +
PF
G/ +
A
N
Rgs
0 20 40 60
100
75
50
25
0
initial
harvest
resistance
harvest
EPZ-5676
100 nM 500 nM
D
GF
IH
A B
93716141
73 sgRNAs
DOT1L
N
HN
N
N
N N
N
NH2
O
HO OH
C
 
hCas9 
GFP
PuroPGK 
U6 EFS 
LTR
sgRNA
hCas9 
negative
selection
RN2 RN2c
positive
selection
Exposure to DOT1L inhibitor EPZ-5676
Harvest cells 
for deep sequencing
Harvest cells 
for deep sequencing 
EPZ-5676
KMT
Pooled sgRNA library
E
Fig 1. KMT domain-focused CRISPR indel mutagenesis reveals a DOT1L allele that confers resistance to EPZ-5676 mediated
growth arrest. (A) Schematic of the vector used to derive clonal MLL-AF9; NrasG12D leukemia RN2c cells that express a human codon-
optimized S. pyogenes Cas9 (hCas9) and the vectors used for lentiviral sgRNA transduction. A GFP reporter was used where indicated to
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KMT-targeting sgRNA #47, but not the control sgRNAs, were initially depleted and later
recovered to>50% GFP positivity by day 30 in culture (Fig 1G and S1 Fig). This result suggests
that sgRNA #47 generates largely loss-of-function alleles of DOT1L, but at a reproducibly low
frequency produces an allele of DOT1L that confers resistance to EPZ-5676.
To identify the EPZ-5676 resistance allele(s) produced by sgRNA #47, we performed deep
sequencing analysis of the exon 8 region of DOT1L KMT domain targeted by this sgRNA in the
resistant cell populations (Fig 1D and 1G). In each of the independently generated CRISPR-
induced resistant cell populations, we observed a pronounced abundance of a combination
deletion/missense mutation in-frame allele that deleted two valines and substituted two flanking
glutamic acid and lysine residues with methionines via point mutations (VVEL293MM) (Fig
1H and S1 Table). This allele was present in low abundance at the initial time point following
transduction with the sgRNA library but came to dominate the cell population following con-
tinuous exposure to EPZ-5676 (S1 Table). The mutation site closely coincided with the pre-
dicted DSB site induced by sgRNA #47 and eliminated the sgRNA recognition sequence,
consistent with an on-target effect (Fig 1H). Importantly, the VVEL293MM allele was not
detected in the parental RN2c cells, and hence can be confidently attributed to CRISPR-medi-
ated mutagenesis. To further evaluate whether the VVEL293MM allele conferred resistance to
EPZ-5676, we retrovirally expressed wild-type or VVEL293MM DOT1L human cDNA in
RN2c cells and performed a titration of EPZ-5676 and measured growth rates. Compared to
wild type DOT1L, the VVEL293MM DOT1L-expressing cells were less sensitive to EPZ-5676
treatment (Fig 1I). Collectively, these findings suggest that DOT1L KMT domain-focused indel
mutagenesis had produced a novel allele that renders leukemia cells resistant to EPZ-5676-
mediated growth arrest.
Biochemical analysis of DOT1L VVEL293MM lysine methyltransferase
activity
We next sought to understand the resistance mechanism of DOT1L VVEL293MM biochemi-
cally. Inspection of the position of the mutation on the available structure of the DOT1L KMT
track sgRNA positive selection. LTR: long terminal repeat promoter, PGK: phosphoglycerate kinase 1 promoter, Puro: puromycin resistance
gene, U6: a Pol III-driven promoter, sgRNA: chimeric single guide RNA, EFS: EF1α promoter, GFP: green fluorescent protein. (B) Schematic
of DOT1L protein domain. A library of 73 sgRNAs was designed targeting the KMT domain of DOT1L. The DOT1L inhibitor EPZ-5676
targets the KMT domain. KMT, lysine methyltransferase. (C) Experimental workflow of domain-focused CRISPR indel mutagenesis
screening. A pooled sgRNA library targeting the DOT1L KMT domain was introduced to RN2c via lentiviral transduction, followed by
continuous exposure to EPZ-5676. Genomic DNA of indicated cell populations was isolated and harvested for sgRNA cassette quantification
and sgRNA-induced indel identification by deep sequencing. (D) CRISPR indel mutagenesis genetic screening of DOT1L identified EPZ-
5676 resistant mutants. The RN2c cells were treated with EPZ-5676 at day 3 post-transduction, in which a fraction of the cells was harvested
and used as a reference time point (day 0). Cells were initially treated with 100 nM of EPZ-5676 at day 0. The inhibitor dosage was increased
to 500 nM at day 20. At day 41, an EPZ-5676 resistant GFP+/sgRNA+ population was identified, harvested, and saved for subsequent deep
sequencing experiments. (E) Quantitative reverse transcription PCR (qRT–PCR) of relative mRNA expression levels in parental and EPZ-
5676 resistant RN2c cell lines after a 6-day treatment with indicated the concentration of EPZ-5676 or DMSO. Results were normalized to
Gapdh, with the relative mRNA level in the DMSO-treated cells set to 1 (n = 3). (F) Pie charts of the relative abundance for 73 individual
sgRNAs at indicated time points. Each slice represents the abundance of a single sgRNA. At day 0 (left), all 73 sgRNAs targeting the DOT1L
KMT domain were detected at roughly equal abundance. At day 41 (right), DOT1L sgRNA #47 dominated the population, representing >95%
of the GFP-positive cells. (G) A proliferation competition assay of RN2c cells transduced with indicated sgRNAs under the treatment of EPZ-
5676 or DMSO shows that DOT1L sgRNA #47 induced mutant(s) confer resistance to EPZ-5676. An sgRNA targeting a Rosa locus and a
random sgRNA targeting the DOT1L KMT domain (DOT1L sgRNA #64) served as negative controls. (H) Nucleotide and protein sequence
diagram of the wild-type and DOT1L mutation induced by sgRNA #47 CRISPR mutagenesis under the treatment of EPZ-5676. Indel
mutations were observed flanking the sgRNA cut site in exon 8 of DOT1L. The indel mutation corresponded to a VVEL to MM mutation at
residue 293. (I) The effect of ectopic overexpression of DOT1L wild-type or mutant on RN2c cell proliferation under the treatment of EPZ-
5676. RN2c cells were retrovirally transduced with wild-type or mutant human DOT1L cDNA. After a 9-day drug treatment, the relative cell
accumulation corresponding to each indicated EPZ-5676 concentrations was measured and normalized to the DMSO treated cells (n = 3).
All error bars shown represent s.e.m.
doi:10.1371/journal.pone.0172177.g001
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domain revealed that these residues were not directly involved in binding to EPZ-5676 [14]
(Fig 2A), thus raising the possibility that the this mutation was conferring resistance to EPZ-
5676 through an alternative mechanism, such as an enhancement of enzymatic activity. We
performed a series of biochemical methyltransferase assays to evaluate this possibility using
recombinant wild-type and VVEL293MM DOT1L KMT domains (Fig 2B), nucleosomal sub-
strates, and radiolabeled S-adenosylmethionine (SAM). Remarkably, we observed that the
VVEL293MM mutant was ~3.6 fold more active KMT relative to the wild-type enzyme (Fig
2C). Mass spectrometry analysis of these methylation reactions validated that H3K79 methyla-
tion was the predominant product of both wild-type and mutant DOT1L enzymes (S2 Fig).
This finding was further corroborated by pre-methylating the substrates with non-radiolabeled
SAM and wild-type DOT1L, which was found to block the ability of DOT1L VVEL293MM to
methylate these nucleosomes (S2 Fig). Taken together, these findings demonstrate that
DOT1L VVEL293MM allele has a hypermorphic, and not a neomorphic, function of H3K79
methyltransferase activity.
We next evaluated the relative sensitivities of the wild-type and VVEL293MM DOT1L to
the EPZ-5676 inhibitor. We increased the reaction volume of the wild type protein by roughly
three-fold in the in vitro methyltransferase activity assays to account for the differential basal
level enzymatic activity between the wild-type and mutant domains. We observed that the
VVEL293MM mutant enzyme was ~2-fold less sensitive to EPZ-5676 compared to the wild-
type (Fig 2D). Collectively, these findings suggest that the VVEL293MM mutation confers two
distinct effects on DOT1L KMT activity: it is a more active enzyme and it is marginally less
sensitive to EPZ-5676. The combination of these two effects is likely to render leukemia cell
growth less-sensitive to EPZ-5676, an effect that is analogous to the hypermorphic BRAF
mutants conferred resistance to targeted therapy in melanoma [4].
Domain-focused CRISPR genetic screening identifies an EZH2 mutant
allele that is resistant to the drug EPZ-6438
To establish the robustness and adaptability of our method, we applied it to another epigenetic
drug target. For this purpose, we focused on EZH2, a histone H3K27 methyltransferase and a
catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) [23]. EZH2 has been the
focus of intense drug discovery efforts in recent years, and several compounds targeting this
KMT have been described, including EPZ-6438 [15]. Moreover, prior studies have demon-
strated that MLL-fusion leukemia cells are addicted to EZH2 enzymatic activity, and hence
RN2c cell line is a suitable model for identifying resistance alleles [24–26].
To generate an EZH2 mutant that confers resistance to EPZ-6438 in cells and thus allows
evaluation of on-target drug effects, we began with a domain-focused CRISPR indel mutagene-
sis screen analogous to the DOT1L screen described above, using a library of all possible
sgRNAs (66 in total) targeting the KMT domain (Fig 3A). RN2c cells were then transduced
with this library and cultured in the presence of 5 μM EPZ-6438. Similar to the observations
with DOT1L, we initially observed a decline of sgRNA+/GFP+ cells (an indicator of EZH2
loss-of-function alleles being produced), followed by a gradual recovery of sgRNA+/GFP+ pop-
ulation after 20 days (Fig 3B). Importantly, the growth rate of RN2c cells at day 42 was dramat-
ically less sensitive to EPZ-6438. A deep sequencing analysis of sgRNA abundance at early and
late time-points revealed an over-representation of sgRNA #52 in the EPZ-6438-resistant cell
population (Fig 3B). Moreover, Sanger sequencing of the EZH2 exonic target site of sgRNA
#52 revealed an in-frame substitution allele, TR678KK, as the candidate resistance mutation
(Fig 3D). To further establish causality between the TR678KK mutation and EPZ-6438 resis-
tance, we cloned wild-type and mutant human EZH2 cDNA into a retroviral expression vector
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Fig 2. Biochemical analysis of DOT1L VVEL293MM lysine methyltransferase activity. (A) Crystal structure of DOT1L KMT domain binding with the
EPZ-5676. The VVEL293MM mutation site was colored in yellow (PDB: 4HRA). (B) SDS-PAGE gel of purified recombinant DOT1L KMT domains of both
wild-type and VVEL293MM mutant proteins. (C) Relative in vitro KMT activity of DOT1L wild-type and VVEL293MM mutant protein. The in vitro KMT activity
was determined by a biochemical methyltransferase assay, which measured the methyltransfer level of radiolabeled SAM to purified nucleosomal substrates
in the presence of a wild-type or mutant enzyme. To ensure that quantifications were made in the linear range of detection, the assay was performed at
several DOT1L concentrations. The top panel shows a representative SDS-PAGE gel autoradiograph of the in vitro KMT assay with KMT proteins and
concentrations of EPZ-5676 indicated. The lower panel plots the average integrated autoradiography intensity from two independent preparations of wild-type
and mutant DOT1L KMT proteins. (D) Relative sensitivities of wild-type and VVEL293MM DOT1L to EPZ-5676. To normalize for the difference in basal
activity between the wild-type and VVEL293MM DOT1L, the in vitro KMT assay reaction volume of the wild-type protein was increased three-fold. The top
panel shows a representative SDS-PAGE gel autoradiograph of the in vitro KMT assay with KMT proteins and EPZ-5676 concentrations indicated. The lower
panel plots the average results from three independent enzymatic preparations. All error bars shown represent s.e.m.
doi:10.1371/journal.pone.0172177.g002
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and tested whether overexpression of the mutation in RN2c cells could shift the sensitivity to
EPZ-6438. Compared to wild-type, TR683KK EHZ2 cDNA overexpression rendered RN2c
growth almost entirely resistant to EPZ-5676 (Fig 3E). Additionally, overexpression of
TR683KK EZH2 cDNA also prevented the transcriptional up-regulation of PRC2-repressed
genes following EPZ-6436 exposure (Fig 3F). These findings suggest that domain-focused
CRISPR indel mutagenesis can be applied more broadly to epigenetic targets to generate novel
resistance alleles, which can be used as definitive tools for evaluating on-target effects of suit-
able chemical probes.
Discussion
In this study we describe a method that employs CRISPR-Cas9 indel mutagenesis to rapidly
derive alleles of endogenous KMT genes that allow definitive demonstration of on-target
effects of chemical inhibitors. While the overwhelming majority of CRISPR-induced indel
mutations are likely to be loss-of-function, particularly when targeting critical enzymatic
domains [11,13], we have shown that rare in-frame alleles can be produced that retain func-
tionality, while simultaneously preventing direct-acting small-molecule inhibitors from caus-
ing cellular growth phenotypes. DOT1L provides an interesting example, in which the allele
that renders cell growth less sensitive to a DOT1L inhibitor works mainly through enhance-
ment of KMT activity. This example is analogous to observations in BRAF, EGFR, and HER2,
in which elevated kinase activity allowed cells to grow in the presence of kinase inhibitors
[4,27]. In the case of DOT1L VVEL293MM, it is likely that enhanced basal level of H3K79
methylation of endogenous chromatin produced by this allele requires a much higher dose of
EPZ-5676 to sufficiently decrease H3K79 methylation levels below the critical threshold to
suppress HOX and MEIS1 expression thereby limiting leukemia growth. However, it is likely
that the modest 2-fold decrease in inhibitor sensitivity of VVEL293MM also contributes to the
resistance phenotype as well. In future work, it will be interesting to evaluate whether indel-
mediated resistance mechanisms generated via CRISPR will favor hypermorphic enzyme
mechanisms instead of abrogation of direct chemical inhibitor binding. During the prepara-
tion of this manuscript, a study by Donovan et al reported a similar conclusion as ours, by
showing that CRISPR-Cas9 indel mutagenesis can generate gain-of-function or inhibitor-
resistant alleles of several kinase targets [28]. Taken together, our two studies suggest that
CRISPR-based indel mutagenesis can be applied to diverse target classes to validate on-target
activity of inhibitors in cells.
The approach described here is complementary to other recently described strategies for
generating resistance alleles. We recently reported the use of domain-swapping as a means to
generate resistance alleles, using the bromodomain protein BRD9 and EZH2 as targets [16].
Recently, several groups have reported methods to create mutants in an endogenous genetic
uM EPZ-6438 at day 3 post-transduction, at which point a fraction of the cells was harvested and used as a reference time point (day 0). At day 42, an
EPZ-6438 resistant sgRNA+/GFP+ population was identified, harvested, and saved for subsequent deep sequencing experiments. (C) Pie charts of
the relative abundance for individual 66 sgRNAs at indicated time points. Each slice represents the abundance of a single sgRNA. At day 0 (left), all 66
sgRNAs targeting the EZH2 KMT domain were detected at roughly equal abundance. At day 42 (right), EZH2 sgRNA #52 dominated the population,
representing >95% of the GFP+ cells. (D) Nucleotide and protein sequence diagram of the wild-type and EZH2 mutation induced by sgRNA #52
CRISPR mutagenesis under the selection pressure of EPZ-6438. The indel mutations were observed in the exon 17 of EZH2 flanking the sgRNA cut
site. Indel mutations were observed in exon 17 of EZH2 flanking the sgRNA cut site. The indel mutation corresponded to a TR to KK mutation from
residue 678. (E) The effect of ectopic overexpression of EZH2 wild-type or TR683KK mutant on RN2c cell proliferation under the treatment of EPZ-
6438. The RN2c cells were retrovirally transduced with wild-type or mutant human EZH2 cDNA. After a 5-day drug treatment, the relative cell
accumulation corresponding to each indicated EPZ-6438 dosage was measured and normalized to the DMSO treated cells (n = 3). (F) qRT–PCR of
relative mRNA expression levels in the indicated cell lines after a 5-day treatment with EPZ-5676 or DMSO. Results were normalized to Gapdh, with
the relative mRNA level in the DMSO-treated cells set to 1 (n = 3). All error bars shown represent s.e.m.
doi:10.1371/journal.pone.0172177.g003
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locus by tethering catalytically dead Cas9 protein with a cytidine deaminase (CRISPR-AID) to
induce base pair mismatches [29,30]. Through manipulation of the DNA mismatch repair
pathway, CRISPR-AID could also generate a pool of missense mutations for screening chemi-
cal inhibitor-resistant mutants [31,32]. The indel mutations generated through error-prone
repair pathways provide a different mutational spectrum that is complementary to the mis-
sense mutations induced by the CRISPR-AID strategies. In this regard, we expect that the
combination of CRISPR-mutagenesis and CRISPR-AID methods to be a powerful tool for
generating inhibitor-resistant mutants and gain-of-function proteins.
Supporting information
S1 Fig. A proliferation competition assay of RN2c cells transduced with indicated sgRNAs
under the treatment of EPZ-5676 or DMSO shows that DOT1L sgRNA #47 induced
mutant(s) confer RN2c resistance to EPZ-5676. An sgRNA targeting a Rosa locus and a ran-
dom sgRNA targeting DOT1L KMT domain (DOT1L sgRNA #64) served as negative controls.
(PDF)
S2 Fig. DOT1L VVEL293MM does not exhibit neomorphic activity on nucleosome sub-
strates. (A) iTRAQ experiments did not detect neomorphic methytransferase activity for the
mutant enzyme. All methylated peptides from the experiment are tabulated and shown as raw
iTRAQ counts (top) or iTRAQ ratios normalized to the wild-type protein reaction (bottom).
(B) Nucleosomes that were first incubated with wild-type enzyme and S-adenosyl methionine
did not show subsequent transfer of radiolabled methyl groups in the presence of either addi-
tional wild-type (lane 1) or mutant protein (lane 2). Both preparations of the enzyme were
active as demonstrated by radiolabeled methyl transfer (lanes 3 and 4), consistent with previ-
ous observations.
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S1 Table. DOT1L KMT domain pooled screen data and DNA oligo sequences.
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